Market Overview

Jazz Pharmaceuticals Up On Allergan, Inc. Rumor


Citing three industry bankers, dealReporter is saying that If Allergan, Inc. was looking for a defensive deal, Jazz Pharmaceuticals (NASDAQ: JAZZ) would likely be most viable target.

Shares of Jazz, which have been the subject of much speculation lately, are getting a big lift on the news, trading higher by 6.8 percent at $167.64. Allergan is also higher by 0.78 percent at $166.80.


Related Articles (JAZZ)

View Comments and Join the Discussion!

Posted-In: News Rumors